Skip to main content

Advertisement

SpringerLink
Log in

Cytotoxicity of Liposomal Paclitaxel in Breast Cancer Cell Line MCF-7

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Regarding that the breast cancer is the most prevalent disease among women, paclitaxel, an anti-cancer drug, could be used in treatment of this disease. As paclitaxel has adverse effects, it was used of nanoliposome drug delivery technology in order to reduce adverse effects and improve drug efficacy. Certain ratios of phosphatidylcholine, cholesterol and paclitaxel were synthesized to prepare nanoliposomal paclitaxel. Using Zeta sizer device, the mean diameter of nanoliposomal paclitaxel was obtained 421.4 nm and its encapsulation efficiency was 91.3 %. By dialysis, drug release in nanoliposome paclitaxel formulation within 28 h was studied which was 5.53 %. This study showed that cytotoxicity effect of nanoliposomal paclitaxel is more than that of the standard form.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Warner E. Clinical practice breast-cancer screening. N Engl J Med. 2011;365:1025–32.

    Article  PubMed  CAS  Google Scholar 

  2. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:73–81.

    Article  Google Scholar 

  3. Guo J, Bourre L, Soden DM, O’Sullivan GC, O’Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol Adv. 2011;29:402–17.

    Article  PubMed  CAS  Google Scholar 

  4. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004–14.

    Article  PubMed  CAS  Google Scholar 

  5. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992;19:646–62.

    PubMed  CAS  Google Scholar 

  6. Greco FA. Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2001;34:53–6.

    Article  Google Scholar 

  7. Dorr RT. Pharmacology and toxicology of cremophor el diluent. Ann Pharmacother. 1994;28:11–4.

    Google Scholar 

  8. Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today. 2012;17:367–78.

    Article  PubMed  CAS  Google Scholar 

  9. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001;1:923–47.

    Article  PubMed  CAS  Google Scholar 

  10. Latif N, Bachhawat BK. Liposomes in immunology. J Biosci. 1984;6:491–502.

    Article  CAS  Google Scholar 

  11. Georgens C, Weyermann J, Zimmer A. Recombinant virus like particles as drug delivery system. Curr Pharm Biotechnol. 2005;6:49–55.

    PubMed  CAS  Google Scholar 

  12. Chen JH, Ling R, Yao Q, Li Y, Chen T, Wang Z, et al. Effect of small-sized liposomal adriamycin administered by various routes on a metastatic breast cancer model. Endocr Relat Cancer. 2005;12:93–100.

    Article  PubMed  CAS  Google Scholar 

  13. Giotta F, Lorusso V, Maiello E, Filippelli G, Valerio MR, Caruso M, et al. Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase ii multicentric study. Ann Oncol. 2007;18:66–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemical Engineering, Lamerd Branch, Islamic Azad University, Lamerd, Iran

    Maedeh Koohi Moftakhari Esfahani, Seyed Ebrahim Alavi, Fatemeh Movahedi & Fatemeh Alavi

  2. Department of Pilot Biotechnology, Pasteur Institute of Iran, Tehran, Iran

    Azim Akbarzadeh

Authors
  1. Maedeh Koohi Moftakhari Esfahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seyed Ebrahim Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatemeh Movahedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fatemeh Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Azim Akbarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Azim Akbarzadeh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esfahani, M.K.M., Alavi, S.E., Movahedi, F. et al. Cytotoxicity of Liposomal Paclitaxel in Breast Cancer Cell Line MCF-7. Ind J Clin Biochem 28, 358–360 (2013). https://doi.org/10.1007/s12291-013-0296-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-013-0296-1

Keywords

Search

Navigation